Welcome to our dedicated page for ISO news (Ticker: ISO), a resource for investors and traders seeking the latest updates and insights on ISO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ISO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ISO's position in the market.
IsoPlexis Corporation (Nasdaq: ISO) has appointed Nachum “Homi” Shamir as Class II director on its Board of Directors. Shamir, previously Chairman and CEO of Luminex Corporation, brings extensive experience in the life sciences sector. He aims to aid IsoPlexis in scaling its innovative lab tools to larger markets. The Board also accepted the resignations of Siddhartha Kadia and Michael Egholm, thanking them for their contributions. The company plans to add a new board member to enhance diversity before its next annual meeting.
IsoPlexis Corporation (Nasdaq: ISO) reported its financial results for Q2 2022, with revenue of $4.0 million, a 7% decline from Q2 2021. Despite operational challenges, including the impact of COVID-19 lockdowns, the company achieved a 31% increase in trailing twelve months revenue, totaling $18.7 million. Operating expenses were reduced by $4.3 million, and the company expects a full-year 2022 revenue increase of at least 20% over 2021. The firm sold 20 new instruments, bringing its installed base to 254, reinforcing its position in the market.
IsoPlexis Corporation (NASDAQ: ISO) will release its Q2 2022 financial results on August 10, 2022, before the market opens. A conference call is scheduled for 5:30 a.m. PT / 8:30 a.m. ET. The event will be available for live streaming on the company's website and archived for later replay.
As a leader in immune cell research, IsoPlexis aids researchers in understanding disease dynamics and therapeutic efficacy, gaining recognition from notable publications and being utilized by major pharmaceutical companies.
IsoPlexis Corporation (Nasdaq: ISO) reported a 52% increase in revenue for Q1 2022, reaching $4.9 million, up from $3.2 million in Q1 2021. The company sold 25 new instruments, expanding the installed base to 234. Despite the growth, operating expenses surged 103% to $30.7 million, leading to an operating loss of $28.1 million and a net loss of $28.7 million. IsoPlexis maintains a 2022 revenue guidance of $26-$27 million, indicating a projected growth of 51% to 56% year-over-year.
IsoPlexis Corporation (Nasdaq: ISO) reported preliminary revenue for Q1 2022, projecting total earnings of $4.8 to $4.9 million, an increase of 48% to 52% from $3.2 million the previous year. The company also announced a strategic initiative to integrate commercial and operational teams, supporting sustainable growth. With an amended credit agreement, IsoPlexis anticipates extending its cash runway into H2 2024 and expects full-year revenue for 2022 to be between $26 million and $27 million, representing 51% to 56% growth over 2021.
IsoPlexis Corporation (NASDAQ: ISO) announced its advancements in cancer immunology at the 2022 AACR Annual Meeting. Utilizing its Duomic™ platform, IsoPlexis has connected T Cell Receptor (TCR) diversity to the most potent single cells, aiming to enhance understanding of tumor infiltrating lymphocytes and personalized neoantigens. The presentation will take place on April 11, 2022, showcasing data on profiling multiplexed functional cytokines and TCRs. This innovative approach is set to improve tracking of immune responses against cancer and infectious diseases.
IsoPlexis Corporation (Nasdaq: ISO) reported significant financial growth for 2021, achieving revenue of $17.3 million, a 66% increase over 2020. The fourth-quarter revenue was $5.5 million, a 63% year-over-year increase. Despite growth, the company's operating loss rose to $76.3 million for 2021 from $27.3 million in 2020, and net loss reached $81.6 million. IsoPlexis anticipates 2022 revenue between $26 million to $27 million, representing 51% to 56% growth over 2021.
IsoPlexis Corporation (Nasdaq: ISO) will release its financial results for Q4 and the full year of 2021 on March 2, 2022, before market open. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET, accessible via the company’s website. The IsoPlexis platform aids researchers by identifying multifunctional single cells, advancing disease understanding, and is recognized for innovation in the field. Their systems are utilized by major pharmaceutical companies and leading cancer centers worldwide.
IsoPlexis Corporation (Nasdaq: ISO), known as the Superhuman Cell Company, announced its participation in several upcoming investor conferences. These include the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, the Cowen 42nd Annual Health Care Conference on March 9, 2022, and the Barclays Global Healthcare Conference on March 15, 2022. Live and archived webcasts will be available on the company's website. IsoPlexis' innovative systems help researchers understand disease progression and treatment efficacy, and have received accolades from major publications.
IsoPlexis Corporation (NASDAQ: ISO) announced a significant study on Long COVID published in Cell. This research, using IsoPlexis’ single-cell functional proteomics platform, involved 309 COVID-19 patients and 457 controls, aiming to identify biological factors linked to Post-Acute Sequelae of COVID-19 (PASC). Findings highlighted correlations between certain immune cell types, particularly T cells and monocytes, and inflammation related to PASC symptoms. The study underscores the potential for early predictive biomarkers to guide treatment and prevention of Long COVID.
FAQ
What is the market cap of ISO (ISO)?
